Bayer buying Perfuse Therapeutics for up to $2.45bn
Germany-based multinational life science company Bayer is to fully acquire San Francisco based biopharmaceutical firm Perfuse Therapeutics for a total potential value of up to $2.45bn, signalling a robust return to strategic merger and acquisition activity. The transaction comprises a $300m upfront cash payment, alongside up to $2.15bn in contingent payments linked to specific development, regulatory, and commercial milestones. The…